Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
BACKGROUND
Irritable bowel syndrome patients demonstrate colonic hypersensitivity after duodenal lipid infusion.


OBJECTIVE
To investigate the role of 5-hydroxytryptamine-3 (5-HT3) receptors in this sensory component of the gastrocolonic response in irritable bowel syndrome.


METHODS
Fifteen female patients with diarrhoea-predominant irritable bowel syndrome completed a trial with the 5-HT3 receptor antagonist alosetron (1 mg b.d.) or placebo (b.d.) over 15 days, followed by the alternative treatment. Each treatment period was followed by a colonic distension trial before and after duodenal lipids. Changes in colonic thresholds, tone and compliance and viscerosomatic referral pattern after lipids were compared between treatments.


RESULTS
With placebo, the colonic thresholds after lipids were significantly reduced for all studied sensations, whereas, with alosetron, the thresholds were significantly reduced only for first sensation and discomfort, but not for gas and pain. The reductions in thresholds did not differ significantly between treatments, but the pain threshold after alosetron tended to be less reduced compared with placebo (P = 0.10). The effects of lipids on tone, compliance and viscerosomatic referral pattern were unaffected by alosetron relative to placebo.


CONCLUSIONS
5-HT3 receptor antagonism reduces the lipid-induced colonic hypersensitivity in irritable bowel syndrome. However, 5-HT3 receptors do not seem to be the principal mediator, but may be a cofactor for the exaggerated sensory component of the gastrocolonic response in irritable bowel syndrome.
Simrén
M
M
Department of Internal Medicine, Sahlgrenska University Hospital, Göteburg, Sweden. magnus.simren@medicien.gu.se
Simms
L
L
D'Souza
D
D
Abrahamsson
H
H
Björnsson
E S
ES
D000328:Adult; D002243:Carbolines / Q000627:therapeutic use*; D002404:Catheterization; D003109:Colonic Diseases, Functional / Q000150:complications / Q000188:drug therapy*; D018592:Cross-Over Studies; D003967:Diarrhea / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology*; D008055:Lipids / Q000009:adverse effects*; D008875:Middle Aged; D011312:Pressure; D011985:Receptors, Serotonin / Q000187:drug effects*; D012677:Sensation; D012684:Sensory Thresholds; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D002243:Carbolines; D008055:Lipids; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C090840:alosetron